epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-512, Phase III. Recruitment complete

Moderate to severe ulcerative colitis

WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.

Where EPI-512 stands on September 30th 2026

  • Randomised471of 471 needed
  • Sites open70of 70 planned
  • Median forecast finishDoneDeadline Sep 2024
  • FinishCompleteRecruitment reached its target.Open the plan
  • Enrolment94% of planRandomised to date against the count the plan expected by now.Open KPIs
  • Sites40 of 70 behindSites below their own expectation. The colour pools every site against what sites of their kind should recruit, so it changes only when the shortfall is more than chance.Open Sites
  • KRIs31 of 70 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
  • QTLsAll 4 withinStudy-level quality limits, judged once enough patients are in.Open QTLs

By country

EPI-512 by country
CountrySites openRandomisedBehindWaiting too long for a first patientOver a KRI threshold
United States20 of 201089 of 2026 of 20
United Kingdom8 of 8236 of 8–5 of 8
Spain10 of 10825 of 1013 of 10
Poland16 of 168712 of 16111 of 16
Turkey8 of 8895 of 8–3 of 8
India8 of 8823 of 8–3 of 8